2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Lung Neoplasms
25
Carcinoma, Non-Small-Cell Lung
6
Lung Diseases
3
Hemoptysis
3
Small Cell Lung Carcinoma
2
Pulmonary Disease, Chronic Obstructive
2
Pneumonia
2
Neoplasms
2
Laryngeal Neoplasms
2
Tuberculosis
1
Smoking
1
Sarcoma
1
Pulmonary Nodule Cm
1
Pulmonary Fibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Precancerous Conditions
1
Oropharyngeal Neoplasms
1
Nasopharyngeal Neoplasms
1
Myeloproliferative Disorders
1
Myelodysplastic-Myeloproliferative Diseases
1
Myelodysplastic Syndromes
1
Mouth Neoplasms
1
Lymphoma, Primary Effusion
1
Lymphoma, B-Cell
1
Lymphoma, AIDS-Related
1
Lung Diseases, Obstructive
1
Lung Diseases, Interstitial
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Infections
1
Interventions
Carboplatin
12
Pemetrexed
8
pembrolizumab
4
Paclitaxel
4
Cisplatin
4
durvalumab
3
Radiosurgery
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
osimertinib
2
camrelizumab
2
atezolizumab
2
Docetaxel
2
taletrectinib
1
repotrectinib
1
motexafin gadolinium
1
exemestane
1
entinostat
1
ceralasertib
1
cemiplimab
1
belinostat
1
belagenpumatucel L
1
alectinib
1
Vinorelbine
1
Tyrosine Kinase Inhibitors
1
TNFSF10 protein, human
1
Radiotherapy
1
Platinum Compounds
1
Patient Reported Outcome Measures
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Bronchogenic
×
Bronchoscopy
×
Clear all
NCT00652769
2017-11-01
BOOST
University College London Hospitals
Phase 3
Completed
168 enrolled